Evidence map›Paper›PMID 39766278›Full record

ArticleBiomolecules2024

Veronica Fertitta, Barbara Varano, Manuela Del Cornò, Paola Fortini, Anna Aureli, Lucia Conti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Harnessing the microbiome for cancer therapy.Nature reviews. Microbiology · 2026
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Veronica FertittaDepartment of Environment and Health, Istituto Superiore di Sanità, 00161 Rome, Italy.
Barbara VaranoCenter for Gender-Specific Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-8780-3775
Manuela Del CornòCenter for Gender-Specific Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-4001-607X
Paola FortiniDepartment of Environment and Health, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0001-6206-8498
Anna AureliInstitute of Translational Pharmacology, National Research Council, 67100 L'Aquila, Italy.ORCID 0000-0003-3533-4265
Lucia ContiCenter for Gender-Specific Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0001-9439-081X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipopolysaccharide (LPS) is a potent endotoxin released at high concentrations in acute infections, causing massive host inflammatory response. Accumulating evidence indicates that dysbiosis-associated chronic low levels of circulating LPS can sustain a prolonged sterile low-grade inflammation that increases the risk of several non-communicable diseases. Interventions aimed at increasing the abundance of beneficial/probiotic bacteria, including

Indexed as

AkkermansiaDendritic CellsEscherichia coliLipopolysaccharidesLymphocyte ActivationSalmonella entericaCell DifferentiationEndotoxinsHumansInterleukin-10Interleukin-6ProbioticsReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesEndotoxinsInterleukin-10Interleukin-6LipopolysaccharidesReceptors, Antigen, T-Cell, gamma-deltaAkkermansia muciniphiladendritic cellsinflammationinnate immunity cellslipopolysaccharidelymphocytesmicrobiota

Identifiers

PMID39766278
PMCPMC11673428

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.